Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, Polymedco to Team up on North American Launch of Colorectal Cancer Test

NEW YORK (GenomeWeb News) – Epigenomics said today it has reached a deal with Polymedco to jointly commercialize Epigenomics' Epi proColon colorectal cancer screen in North America.

The test is currently under review by the US Food and Drug Administration, and Germany-based Epigenomics has said that approval is anticipated later this year. Upon approval, Polymedco would deploy its dedicated colorectal cancer sales force, technical support staff, administration, logistics, and other support functions to launch and market the test, Epigenomics said.

Both firms will jointly work on marketing, launch, and development strategies, and collaborate on reimbursement efforts for Epi proColon. Epigenomics will continue to be responsible for manufacturing the test, and for supporting it "from the medical and regulatory point of view, including the activities necessary to achieve inclusion in major cancer screening guidelines" after FDA approval, it said.

As part of the deal, Epigenomics and Polymedco have agreed to a combined transfer price and to share profits, subject to minimum annual sales of test kits to Polymedco.

Based in Cortlandt Manor, NY, Polymedco is the largest provider of colorectal cancer screening tests in North America, according to Epigenomics, and has more than $50 million in annual sales of cancer diagnostic products. Its customer base includes more than 1,500 laboratories.

"Polymedco's commitment to the [colorectal cancer] screening space will accelerate our commercial rollout in North America and will mean a significant time and resource advantage for Epigenomics in the launch of Epi proColon," Noel Doheny, CEO of Epigenomics' US subsidiary, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more